Beam Therapeutics INC 10-Q quarterly reports

Beam Therapeutics reports on advancements in its gene editing therapies for sickle cell disease and AATD, alongside a substantial net loss and ongoing need for capital.

Beam Therapeutics reports a significant increase in license and collaboration revenue in Q1 2026, alongside a reduction in net loss, driven by milestone achievements and strategic financing.

Beam Therapeutics reported an increased net loss in Q3 2025 due to higher R&D expenses, despite positive clinical updates for its BEAM-101 and BEAM-302 programs and a significant capital raise.

Beam Therapeutics reports progress in its clinical trials for sickle cell disease and AATD, alongside a strong cash position, despite increased operating losses.

Beam Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and strategic collaborations.

Beam Therapeutics' Q3 2024 report details financial results, clinical trial progress, and strategic advancements in their gene editing programs.

Beam Therapeutics reported its second quarter 2024 financial results and provided updates on its clinical programs, including progress in its BEACON trial for sickle cell disease and the initiation of a Phase 1/2 trial for BEAM-302 in AATD.

Beam Therapeutics reported its first quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.